RESUMO
INTRODUCTION: hepatitis C patients loss to follow-up in the health care system has been shown to have negative consequences. This study aimed to investigate this issue as regards primary biliary cholangitis. METHODS: the databases (immunology, biochemistry, clinical reports, drug dispensation, appointments) of 4 reference hospitals in Spain (serving a population of 1,450,000 inhabitants) were analyzed. The diagnosis of primary biliary cholangitis was based on an antimitochondrial antibody titer ≥ 1:80, chronically elevated alkaline phosphatase, and the absence of other liver disease. Patients were classified as lost in the absence of reports indicating a diagnosis, specific medical follow-up, and/or treatment with bile salts. RESULTS: a total of 1372 patients with antimitochondrial antibody titers ≥ 1:80 were included between January 2010 and June 2019. A total of 697 (50.8 %) were classified as having primary biliary cholangitis, and 100 patients (14.3 %; 95 % CI: 11.8-17.2) were identified as lost. Of these, 30 were contacted and retrieved. The median age was 70 years, 93 % were female, median alkaline phosphatase was 185 IU/L, 10 % had pruritus, and 27 % had a transient elastography value > 9.5 kPa. The disease was confirmed and ursodeoxycholic acid was started in all 30 patients. Death was liver-related in 6 of the 100 patients classified as lost. CONCLUSION: up to 14.3 % of patients (1 out of 7) with a definitive diagnosis of primary biliary cholangitis remain undiagnosed, thus preventing monitoring and treatment. More than a quarter are at risk of advanced liver disease and its complications. Patients lost in the system must be identified and retrieved, and searching hospital databases is a suitable approach to meet this goal.
Assuntos
Colangite , Cirrose Hepática Biliar , Idoso , Fosfatase Alcalina , Colangite/tratamento farmacológico , Colangite/epidemiologia , Feminino , Humanos , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/tratamento farmacológico , Cirrose Hepática Biliar/epidemiologia , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
Direct-acting antiviral agents (DAA) combining daclatasvir (DCV) have reported good outcomes in the recurrence of hepatitis C virus (HCV) infection after liver transplant (LT). However, its effect on the severe recurrence and the risk of death remains controversial. We evaluated the efficacy, predictors of survival, and safety of DAC-based regimens in a large real-world cohort. A total of 331 patients received DCV-based therapy. Duration of therapy and ribavirin use were at the investigator's discretion. The primary end point was sustained virological response (SVR) at week 12. A multivariate analysis of predictive factors of mortality was performed. Intention-to-treat (ITT) and per-protocol SVR were 93.05% and 96.9%. ITT-SVR was lower in cirrhosis (n = 163) (96.4% vs. 89.6% P = 0.017); the SVR in genotype 3 (n = 91) was similar, even in advanced fibrosis (96.7% vs. 88%, P = 0.2). Ten patients (3%) experienced virological failure. Therapy was stopped in 18 patients (5.44%), and ten died during treatment. A total of 22 patients (6.6%) died. Albumin (HR = 0.376; 95% CI 0.155-0.910) and baseline MELD (HR = 1.137; 95% CI: 1.061-1.218) were predictors of death. DCV-based DAA treatment is efficacious and safe in patients with HCV infection after LT. Baseline MELD score and serum albumin are predictors of survival irrespective of viral response.
Assuntos
Antivirais/uso terapêutico , Hepatite C/tratamento farmacológico , Imidazóis/uso terapêutico , Transplante de Fígado , Complicações Pós-Operatórias/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Carbamatos , Feminino , Hepatite C/mortalidade , Hepatite C/virologia , Humanos , Terapia de Imunossupressão , Masculino , Pessoa de Meia-Idade , Pirrolidinas , Recidiva , Estudos Retrospectivos , Espanha/epidemiologia , Resposta Viral Sustentada , Valina/análogos & derivadosRESUMO
INTRODUCTION: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. The ART score has recently been proposed as a method of identifying patients who are eligible or not for a second TACE procedure. OBJECTIVE: To assess the validity of the Assessment for Retreatment with TACE (ART) score in a cohort of patients treated with drug-eluting bead TACE (DEB-TACE). SECONDARY OBJECTIVE: to identify clinical determinants associated with overall survival (OS). METHOD: A retrospective, multicentre study conducted in Spain in patients with HCC having undergone two or more DEB-TACE procedures between January 2009 and December 2014. The clinical characteristics and OS from the day before the second DEB-TACE of patients with a high ART score (ART≥2.5) and a low ART score (ART 0-1) were compared. Risk factors for mortality were identified using Cox's proportional hazards model. RESULTS: Of the 102 patients included, 51 scored 0-1.5 and 51 scored ≥2.5. Hepatitis C was more frequent in patients scoring ≥2.5. Median OS from the day before the second DEB-TACE was 21 months (95% CI, 15-28) in the group scoring 0-1.5, and 17 months (95% CI, 10-25) in the group scoring ≥2.5 (P=0.3562). Platelet count and tumour size, but not the ART score, were independent baseline predictors of OS. CONCLUSIONS: The ART score is not suitable for guiding DEB-TACE retreatment according to Spanish clinical practice standards.
Assuntos
Carcinoma Hepatocelular/terapia , Quimioembolização Terapêutica/métodos , Neoplasias Hepáticas/terapia , Seleção de Pacientes , Índice de Gravidade de Doença , Idoso , Carcinoma Hepatocelular/epidemiologia , Carcinoma Hepatocelular/mortalidade , Quimioembolização Terapêutica/efeitos adversos , Comorbidade , Implantes de Medicamento , Feminino , Artéria Hepática , Hepatite C Crônica/epidemiologia , Humanos , Estimativa de Kaplan-Meier , Cirrose Hepática Alcoólica/epidemiologia , Testes de Função Hepática , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/mortalidade , Masculino , Microesferas , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Resultado do TratamentoRESUMO
INTRODUCTION: Anorexia nervosa (AN) is characterised by a refusal to normal body weight accompanied by a marked restriction of food intake, frequently leading to severe malnutrition. In severe malnutrition and wasting syndromes, mucosal atrophy, altered gastrointestinal motility and pancreatic atrophy, which alter digestive function and can exacerbate malnutrition, have been described. The objective of this work was to determine intestinal absorption and pancreatic function in severely malnourished AN patients before and after recovery. METHODS: Ten severely malnourished AN women were studied at hospital admittance (body mass index = 11.44-16.16 kg/m(2)) and after weight recovery with artificial nutrition (body mass index ≥ 20 kg/m(2)). A (13)C-labelled triglycerides digestion test, faecal elastase test and d-xylose absorption test were performed. RESULTS: In nine patients, (13)C-labelled triglycerides digestion tests and the faecal elastase and d-xylose tests were normal both before and after weight recovery. In one patient, the results were abnormal, and they led to the detection of a previously undiagnosed celiac disease in addition to her AN. CONCLUSION: In this series, there was neither intestinal absorption nor pancreatic function disturbances in severely malnourished AN patients either before or after weight recovery. The usefulness of these tests in the differentiation of functional versus structural changes needs further studies.
Assuntos
Anorexia Nervosa/fisiopatologia , Absorção Intestinal/fisiologia , Desnutrição/fisiopatologia , Pâncreas/fisiopatologia , Absorção , Adulto , Anorexia Nervosa/terapia , Composição Corporal , Feminino , Humanos , Desnutrição/terapia , Estado NutricionalRESUMO
Percutaneous ablation procedures are minimally invasive treatments for unresectable early stage hepatocellular carcinoma (HCC). These techniques are usually safe, but rare and even fatal complications have been described. We present a fatal result after percutaneous ethanol injection (PEI) for the treatment of a recurrent HCC in a non-cirrhotic liver, with subsequent development of diffuse cholangitis and multiple liver abscesses. Although percutaneous drainage and intensive antibiotic treatment were employed, the patient finally died. We discuss about the etiology and the physiopathology of this rare complication in which the therapeutic options are limited and usually unsuccessful.
Assuntos
Técnicas de Ablação/efeitos adversos , Carcinoma Hepatocelular/terapia , Colangite/etiologia , Etanol/administração & dosagem , Abscesso Hepático/etiologia , Neoplasias Hepáticas/terapia , Recidiva Local de Neoplasia/terapia , Técnicas de Ablação/métodos , Idoso , Evolução Fatal , Humanos , Injeções Intralesionais , Abscesso Hepático/patologia , MasculinoRESUMO
Chronic hepatitis C virus (HCV) infection is the main cause of liver cirrhosis and liver carcinoma in western countries. There is evidence that HCV clearance induced by antiviral therapy is beneficial, increasing survival and reducing the complications of cirrhosis. Triple therapy with boceprevir or telaprevir associated with pegylated interferon and ribavirin has increased rates of sustained viral response both in treatment-naïve patients and in those failing previous regimens. Before treating patients with these new molecules, physicians should be familiar with their indications and the regimens to be used. Furthermore, both adverse events and the development of resistances must be monitored. The main aims are careful selection of patients and of the regimen to be used, and achieving adequate adherence to obtain optimal results.
Assuntos
Antivirais/administração & dosagem , Hepatite C Crônica/tratamento farmacológico , Quimioterapia Combinada , Hepatite C Crônica/complicações , Humanos , Interferon alfa-2 , Interferon-alfa/administração & dosagem , Oligopeptídeos/administração & dosagem , Polietilenoglicóis/administração & dosagem , Prolina/administração & dosagem , Prolina/análogos & derivados , Proteínas Recombinantes/administração & dosagem , Ribavirina/administração & dosagemRESUMO
We present the case of a liver transplant recipient with alcoholic liver cirrhosis and early-stage hepatocellular carcinoma who developed biopsy-proven acute steroid-resistant rejection 3 months after liver transplantation. After the failure of immunosuppressive therapy with intravenous boluses of 6-methyl-prednisolone and switching of the immunosuppressive regimen to tacrolimus plus mycophenolate mofetil, two doses of intravenous basiliximab were administered four days apart. Clinical, analytical, and biopsy-proven histological response was complete. No basiliximab-related adverse events were detected. Basiliximab may represent an alternative in liver transplantation immunosuppression to treat acute steroid-resistant rejection, without increasing the incidence of infections, neoplasms, or other adverse events, as shown by this case.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Rejeição de Enxerto/tratamento farmacológico , Transplante de Fígado , Proteínas Recombinantes de Fusão/uso terapêutico , Doença Aguda , Basiliximab , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/cirurgia , Ciclosporina/uso terapêutico , Resistência a Medicamentos , Humanos , Imunossupressores/uso terapêutico , Cirrose Hepática Alcoólica/complicações , Cirrose Hepática Alcoólica/cirurgia , Testes de Função Hepática , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/cirurgia , Masculino , Metilprednisolona/farmacologia , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Pregnenodionas/farmacologia , Pregnenodionas/uso terapêutico , Receptores de Interleucina-2/antagonistas & inibidores , Receptores de Interleucina-2/imunologia , Tacrolimo/uso terapêuticoAssuntos
Antirreumáticos/uso terapêutico , Hepatite Autoimune/tratamento farmacológico , Infliximab/uso terapêutico , Doença Aguda , Adulto , Azatioprina/uso terapêutico , Substituição de Medicamentos , Feminino , Hepatite Autoimune/complicações , Humanos , Hipotireoidismo/complicações , Imunossupressores/uso terapêutico , Prednisona/uso terapêutico , Indução de RemissãoRESUMO
Aim: This study aimed: to develop and validate an LC-MS/MS method for mycophenolic acid, tacrolimus, sirolimus, everolimus and cyclosporin A in oral fluid (OF), as an essential tool to study the usefulness of OF as an alternative matrix for immunossuppressants' therapeutic drug monitoring; and to find the best OF collector for these analytes. Materials & Methods: Chromatographic separation was achieved using an XBridge® Shield RP18 analytical column maintained at 65ºC, using 2 mM ammonium formate and 0.1% formic acid in water (A) and acetonitrile (B) as mobile phase. OF sample was extracted with solid phase extraction after sonication and protein precipitation. Results & Conclusions: Method validation met all the acceptance criteria. LODs were 0.05-1 ng/ml, and LOQs 0.1-5 ng/ml. Silanized tubes offered the best recoveries. The method was successfully applied to 31 OF specimens, describing everolimus detection in OF for the first time. Conclusion: The proposed method is sensitive enough for the detection of OF trough concentrations in patients receiving immunosuppressants when using an appropriate OF collector.
Assuntos
Líquidos Corporais/química , Cromatografia Líquida/métodos , Testes de Química Clínica/métodos , Imunossupressores/análise , Espectrometria de Massas em Tandem/métodos , Calibragem , Humanos , Imunossupressores/isolamento & purificação , Limite de Detecção , Reprodutibilidade dos TestesRESUMO
Introduction: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. The ART score has recently been proposed as a method of identifying patients who are eligible or not for a second TACE procedure. Objective: To assess the validity of the Assessment for Retreatment with TACE (ART) score in a cohort of patients treated with drug-eluting bead TACE (DEB-TACE). Secondary objective: to identify clinical determinants associated with overall survival (OS). Method: A retrospective, multicentre study conducted in Spain in patients with HCC having undergone two or more DEB-TACE procedures between January 2009 and December 2014. The clinical characteristics and OS from the day before the second DEB-TACE of patients with a high ART score (ART≥2.5) and a low ART score (ART 0-1) were compared. Risk factors for mortality were identified using Cox's proportional hazards model. Results: Of the 102 patients included, 51 scored 0-1.5 and 51 scored ≥2.5. Hepatitis C was more frequent in patients scoring ≥2.5. Median OS from the day before the second DEB-TACE was 21 months (95% CI, 15-28) in the group scoring 0-1.5, and 17 months (95% CI, 10-25) in the group scoring ≥2.5 (P=0.3562). Platelet count and tumour size, but not the ART score, were independent baseline predictors of OS. Conclusions: The ART score is not suitable for guiding DEB-TACE retreatment according to Spanish clinical practice standards (AU)
Introducción: La selección de los candidatos ideales con carcinoma hepatocelular (CHC) que más se benefician de realizar quimioembolización transarterial (TACE) sigue siendo un reto. Recientemente se ha propuesto el índice ART para seleccionar a aquellos pacientes tributarios o no de realizar un segundo procedimiento de TACE. Objetivo: Evaluar la validez del índice ART en una cohorte tratada con TACE con partículas cargadas (DEB-TACE). Objetivo secundario: identificar los factores clínicos asociados con la supervivencia global. Método: Estudio retrospectivo multicéntrico español en pacientes con CHC tratados con≥2 DEB-TACE entre enero del 2009 y diciembre del 2014. Se compararon las características clínicas y la supervivencia global desde el día previo a la segunda DEB-TACE entre los pacientes con ART alto (ART≥2,5) y bajo (ART 0-1). Los factores de riesgo de mortalidad se identificaron usando el modelo de riesgos proporcionales de Cox. Resultados: De los 102 pacientes incluidos, 51 obtuvieron puntuación de 0-1,5 y 51 ≥ 2,5. La hepatitis C fue más frecuente en pacientes con puntuación ≥ 2,5. La supervivencia global mediana desde el día previo a DEB-TACE-2 fue de 21 meses (IC del 95%, 15-28) y de 17 meses (IC del 95%, 10-25) en los pacientes con ART 0-1,5 y ≥ 2,5, respectivamente (p=0,3562). Los factores basales predictores independientes de supervivencia fueron el recuento de plaquetas y el tamaño del tumor, pero no el índice ART. Conclusiones: El índice ART no es adecuado para guiar el retratamiento con DEB-TACE según los estándares de práctica clínica español (AU)
Assuntos
Humanos , Carcinoma Hepatocelular/terapia , Neoplasias Hepáticas/terapia , Quimioembolização Terapêutica , Risco Ajustado/métodos , Seleção de Pacientes , Reprodutibilidade dos Testes , Fatores de Risco , Análise de Sobrevida , Estudos Retrospectivos , Estadiamento de NeoplasiasRESUMO
Percutaneous ablation procedures are minimally invasive treatments for unresectable early stage hepatocellular carcinoma (HCC). These techniques are usually safe, but rare and even fatal complications have been described. We present a fatal result after percutaneous ethanol injection (PEI) for the treatment of a recurrent HCC in a non-cirrhotic liver, with subsequent development of diffuse cholangitis and multiple liver abscesses. Although percutaneous drainage and intensive antibiotic treatment were employed, the patient finally died. We discuss about the etiology and the physiopathology of this rare complication in which the therapeutic options are limited and usually unsuccessful(AU)
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Colangite/induzido quimicamente , Colangite/complicações , Colangite/diagnóstico , Etanol/uso terapêutico , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/diagnóstico , Antibioticoprofilaxia/métodos , Antibioticoprofilaxia , Colangite/cirurgia , Colangite , Carcinoma Hepatocelular , Hepatectomia , Abscesso/fisiopatologia , Abscesso , Imageamento por Ressonância Magnética/métodos , Imageamento por Ressonância Magnética/tendências , Imageamento por Ressonância MagnéticaAssuntos
Carcinoma de Células Renais , Carcinoma de Células Escamosas , Neoplasias Esofágicas , Neoplasias Renais , Transplante de Fígado , Neoplasias Primárias Múltiplas , Idoso , Biópsia por Agulha Fina , Evolução Fatal , Humanos , Cirrose Hepática Alcoólica/cirurgia , Masculino , Tomografia Computadorizada por Raios XRESUMO
Resumen La infección crónica por el virus de la hepatitis C (VHC) es la principal causa de cirrosis hepática y hepatocarcinoma en los países occidentales. Existe evidencia para afirmar que el aclaramiento del VHC inducido por la terapia antiviral proporciona beneficio con incremento de la supervivencia y disminución de las complicaciones derivadas de la cirrosis. La triple terapia con boceprevir o telaprevir asociados a interferón pegilado y ribavirina ha incrementado las tasas de respuesta viral sostenida tanto en pacientes no tratados previamente como en aquellos en los que ha fallado una pauta previa de tratamiento. El manejo del tratamiento con estas nuevas moléculas requiere familiarizarse con las indicaciones y pautas a emplear, así como con los eventos adversos y la monitorización del desarrollo de resistencias. Los objetivos fundamentales son una selección cuidadosa del paciente y del régimen terapéutico que se va a emplear, así como lograr una adherencia adecuada que permita obtener óptimos resultados de eficacia (AU)
Abstract Chronic hepatitis C virus (HCV) infection is the main cause of liver cirrhosis and liver carcinoma in western countries. There is evidence that HCV clearance induced by antiviral therapy is beneficial, increasing survival and reducing the complications of cirrhosis. Triple therapy with boceprevir or telaprevir associated with pegylated interferon and ribavirin has increased rates of sustained viral response both in treatment-naïve patients and in those failing previous regimens. Before treating patients with these new molecules, physicians should be familiar with their indications and the regimens to be used. Furthermore, both adverse events and the development of resistances must be monitored. The main aims are careful selection of patients and of the regimen to be used, and achieving adequate adherence to obtain optimal results (AU)
Assuntos
Humanos , Hepatite C Crônica/tratamento farmacológico , Antivirais/uso terapêutico , Carga Viral , Hepacivirus/patogenicidade , Seleção de Pacientes , Tolerância a Medicamentos , /estatística & dados numéricosRESUMO
Se presenta el caso de un receptor de un trasplante hepático con la indicación de cirrosis hepática alcohólica y carcinoma hepatocelular en estadio inicial que presentó un rechazo celular agudo resistente a los corticoides demostrado por biopsia a los 3 meses del trasplante. Tras la ausencia de mejora analítica o histológica con 6-metil-prednisolona intravenosa y la conversión del régimen inmunosupresor a tacrolimus y micofenolato mofetil, se administraron 2 dosis de basiliximab intravenoso separadas por 4 días, asistiendo a la normalización clínica, analítica e histológica. No se detectaron episodios adversos relacionados con el tratamiento con basiliximab. El basiliximab puede representar una opción terapéutica en el rechazo celular agudo resistente a los corticoides tras el trasplante hepático, sin que se hayan observado infecciones, neoplasias ni otros efectos adversos potencialmente relacionados en este caso (AU)
We present the case of a liver transplant recipient with alcoholic liver cirrhosis and early-stage hepatocellular carcinoma who developed biopsy-proven acute steroid-resistant rejection 3 months after liver transplantation. After the failure of immunosuppressive therapy with intravenous boluses of 6-methyl-prednisolone and switching of the immunosuppressive regimen to tacrolimus plus mycophenolate mofetil, two doses of intravenous basiliximab were administered four days apart. Clinical, analytical, and biopsy-proven histological response was complete. No basiliximab-related adverse events were detected. Basiliximab may represent an alternative in liver transplantation immune suppression to treat acute steroid-resistant rejection, without increasing the incidence of infections, neoplasms, or other adverse events, as shown by this case (AU)